Foghorn Therapeutics Reports Officer/Director Changes, Comp Arrangements
Ticker: FHTX · Form: 8-K · Filed: Jan 3, 2024 · CIK: 1822462
| Field | Detail |
|---|---|
| Company | Foghorn Therapeutics Inc. (FHTX) |
| Form Type | 8-K |
| Filed Date | Jan 3, 2024 |
| Risk Level | medium |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.0001 |
| Sentiment | neutral |
Complexity: simple
Sentiment: neutral
Topics: executive-changes, compensation, corporate-governance
TL;DR
**Foghorn Therapeutics filed an 8-K about executive changes and compensation on Dec 29, 2023.**
AI Summary
Foghorn Therapeutics Inc. filed an 8-K on January 3, 2024, reporting an event that occurred on December 29, 2023. This filing indicates changes related to 'Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers' and 'Financial Statements and Exhibits'. While the specific details of these changes are not provided in this summary, investors should be aware that executive or board-level changes, especially those involving compensation, can signal shifts in company strategy or performance, potentially impacting future stock value.
Why It Matters
Changes in leadership or executive compensation can signal strategic shifts or financial health concerns, directly influencing investor confidence and the company's future direction.
Risk Assessment
Risk Level: medium — The filing indicates significant changes in leadership and compensation, which can introduce uncertainty regarding future company performance and strategy.
Analyst Insight
A smart investor would seek out further details regarding the specific officers or directors involved and the nature of the compensatory arrangements to assess the potential impact on company strategy and financial health.
Key Players & Entities
- Foghorn Therapeutics Inc. (company) — the registrant filing the 8-K
- December 29, 2023 (date) — date of the earliest event reported
- January 3, 2024 (date) — date the 8-K was filed
- 001-39634 (other) — Commission File Number
- 500 Technology Square, Ste 700 Cambridge, MA 02139 (other) — principal executive offices address
FAQ
What was the earliest event reported in this 8-K filing?
The earliest event reported in this 8-K filing occurred on December 29, 2023.
What specific items are covered in this 8-K filing by Foghorn Therapeutics Inc.?
This 8-K filing covers 'Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers' and 'Financial Statements and Exhibits'.
When was this 8-K filing submitted to the SEC?
This 8-K filing was submitted to the SEC on January 3, 2024.
What is the business address of Foghorn Therapeutics Inc. as stated in the filing?
The business address of Foghorn Therapeutics Inc. is 500 Technology Square, Ste 700, Cambridge, MA 02139.
What is the Commission File Number for Foghorn Therapeutics Inc.?
The Commission File Number for Foghorn Therapeutics Inc. is 001-39634.
Filing Stats: 512 words · 2 min read · ~2 pages · Grade level 11.1 · Accepted 2024-01-03 16:18:12
Key Financial Figures
- $0.0001 — ge on which registered Common Stock, $0.0001 par value per share FHTX The Nasdaq Glo
Filing Documents
- fhtx-20231229.htm (8-K) — 32KB
- exhibit991foghorncfodepart.htm (EX-99.1) — 9KB
- 0001628280-24-000199.txt ( ) — 171KB
- fhtx-20231229.xsd (EX-101.SCH) — 2KB
- fhtx-20231229_lab.xml (EX-101.LAB) — 24KB
- fhtx-20231229_pre.xml (EX-101.PRE) — 13KB
- fhtx-20231229_htm.xml (XML) — 3KB
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits 99.1 Press release issued on January 3 , 202 4
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. FOGHORN THERAPEUTICS INC. By: /s/ Michael J. LaCascia Michael J. LaCascia Chief Legal Officer Date: January 3, 2024